CRISPR/Cas9 screening identifies a kinetochore‐microtubule dependent mechanism for Aurora‐A inhibitor resistance in breast cancer

BACKGROUND: Overexpression of Aurora‐A (AURKA) is a feature of breast cancer and associates with adverse prognosis. The selective Aurora‐A inhibitor alisertib (MLN8237) has recently demonstrated promising antitumor responses as a single agent in various cancer types but its phase III clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ailin, Wen, Shijun, Liu, Fang, Zhang, Zijian, Liu, Meiling, Wu, Yuanzhong, He, Bin, Yan, Min, Kang, Tiebang, Lam, Eric W‐F, Wang, Zifeng, Liu, Quentin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896750/
https://www.ncbi.nlm.nih.gov/pubmed/33471959
http://dx.doi.org/10.1002/cac2.12125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896750/
https://www.ncbi.nlm.nih.gov/pubmed/33471959
http://dx.doi.org/10.1002/cac2.12125

Ejemplares similares